KR20230163443A - 나노겔 피복형 백신 - Google Patents

나노겔 피복형 백신 Download PDF

Info

Publication number
KR20230163443A
KR20230163443A KR1020237035571A KR20237035571A KR20230163443A KR 20230163443 A KR20230163443 A KR 20230163443A KR 1020237035571 A KR1020237035571 A KR 1020237035571A KR 20237035571 A KR20237035571 A KR 20237035571A KR 20230163443 A KR20230163443 A KR 20230163443A
Authority
KR
South Korea
Prior art keywords
nanogel
vlp
pro
leu
val
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020237035571A
Other languages
English (en)
Korean (ko)
Inventor
히로시 기요노
요시카즈 유키
Original Assignee
고쿠리츠다이가쿠호우진 도쿄다이가쿠
가부시키가이샤 하나벡스
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 고쿠리츠다이가쿠호우진 도쿄다이가쿠, 가부시키가이샤 하나벡스 filed Critical 고쿠리츠다이가쿠호우진 도쿄다이가쿠
Publication of KR20230163443A publication Critical patent/KR20230163443A/ko
Pending legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/39Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/54Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541Mucosal route
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/54Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541Mucosal route
    • A61K2039/543Mucosal route intranasal
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55555Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55583Polysaccharides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/57Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/60Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6087Polysaccharides; Lipopolysaccharides [LPS]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/64Medicinal preparations containing antigens or antibodies characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011Details
    • C12N2770/16011Caliciviridae
    • C12N2770/16034Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
KR1020237035571A 2021-03-30 2022-03-28 나노겔 피복형 백신 Pending KR20230163443A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2021056392 2021-03-30
JPJP-P-2021-056392 2021-03-30
PCT/JP2022/014798 WO2022210465A1 (ja) 2021-03-30 2022-03-28 ナノゲル被覆型ワクチン

Publications (1)

Publication Number Publication Date
KR20230163443A true KR20230163443A (ko) 2023-11-30

Family

ID=83459198

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020237035571A Pending KR20230163443A (ko) 2021-03-30 2022-03-28 나노겔 피복형 백신

Country Status (8)

Country Link
US (1) US20240181033A1 (https=)
EP (1) EP4316511A4 (https=)
JP (1) JPWO2022210465A1 (https=)
KR (1) KR20230163443A (https=)
CN (1) CN117098549A (https=)
AU (1) AU2022248775A1 (https=)
CA (1) CA3212267A1 (https=)
WO (1) WO2022210465A1 (https=)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000012564A1 (en) 1998-08-31 2000-03-09 Nof Corporation High-purity polysaccharide containing hydrophobic groups and process for producing the same
JP2010105968A (ja) 2008-10-31 2010-05-13 Tokyo Medical & Dental Univ カチオン性ナノゲルを用いる粘膜ワクチン

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020019754A (ja) * 2018-08-03 2020-02-06 国立研究開発法人農業・食品産業技術総合研究機構 ウシ乳房炎に対する粘膜ワクチン組成物

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000012564A1 (en) 1998-08-31 2000-03-09 Nof Corporation High-purity polysaccharide containing hydrophobic groups and process for producing the same
JP2010105968A (ja) 2008-10-31 2010-05-13 Tokyo Medical & Dental Univ カチオン性ナノゲルを用いる粘膜ワクチン

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
Ayame 등, Bioconjugate Chem 19 : 882-890 2008
Kong 등, Infect Immun 81 : 1625-1634 2013
Nochi 등, Nat Mater 9 : 572-578 2010
Yuki 등, Biotechnol Genet Eng Rev 29 : 61-72 2013
Yuki 등, Mol. Pharmaceutics, 18 : 1582-1592 2021

Also Published As

Publication number Publication date
AU2022248775A1 (en) 2023-10-12
US20240181033A1 (en) 2024-06-06
CN117098549A (zh) 2023-11-21
JPWO2022210465A1 (https=) 2022-10-06
CA3212267A1 (en) 2022-10-06
WO2022210465A1 (ja) 2022-10-06
EP4316511A1 (en) 2024-02-07
EP4316511A4 (en) 2025-05-21

Similar Documents

Publication Publication Date Title
Safarzadeh et al. Chitin and chitosan as tools to combat COVID-19: A triple approach
Mosafer et al. Preparation, characterization and in vivo evaluation of alginate-coated chitosan and trimethylchitosan nanoparticles loaded with PR8 influenza virus for nasal immunization
Lin et al. Enhanced immune responses to mucosa by functionalized chitosan-based composite nanoparticles as a vaccine adjuvant for intranasal delivery
KR101342641B1 (ko) 폴리감마글루탐산-키토산 나노입자를 함유하는 면역보강제 조성물
Li et al. A" trained immunity" inducer-adjuvanted nanovaccine reverses the growth of established tumors in mice
KR20090079912A (ko) 노로바이러스 백신 제제
KR20150102995A (ko) 경비 인플루엔자 백신 조성물
Wu et al. Enhancing antibacterial immunotherapy for bacterial pneumonia via nanovaccines coated with outer membrane vesicles
CN116981448A (zh) 包括工程化的植物来源的细胞外囊泡的组合物及其用作疫苗的用途
EP3403671B1 (en) Vaccine containing immobilized virus particles
Zhao et al. Dendrigraft poly-L-lysines delivery of DNA vaccine effectively enhances the immunogenic responses against H9N2 avian influenza virus infection in chickens
Piri-Gharaghie et al. RETRACTED ARTICLE: Novel adjuvant nano-vaccine induced immune response against Acinetobacter baumannii
CN110613844A (zh) 一种迷你联合佐剂纳米颗粒及其制备方法和应用
US20150023909A1 (en) Lymph node-targeting nanoparticles
Witeof et al. Atomic-layer deposition processes applied to phage λ and a phage-like particle platform yield thermostable, single-shot vaccines
Iyer et al. Bioengineering strategies for developing vaccines against respiratory viral diseases
JP2020504179A (ja) 汎用インフルエンザワクチン組成物
CN112569348B (zh) 一种带状疱疹疫苗
Li et al. Enhancing humoral and mucosal immune response of PED vaccine candidate by fusing S1 protein to nanoparticle multimerization
Hemmaty Effectiveness of chitosan nanoparticles in development of pentavalent clostridial toxoid vaccine in terms of clinical pathology elements and immunological responses
CN112089834B (zh) 基于氧化石墨烯的茯苓多糖纳米佐剂及佐剂/抗原共递送疫苗的制备与应用
US9833407B2 (en) Nasal vaccine for Streptococcus pneumoniae
US20200306364A1 (en) Mucoadhesive nanoparticle entrapped influenza virus vaccine delivery system
Jin et al. N-2-hydroxypropyl trimethyl ammonium chloride chitosan-aluminum nano-adjuvant elicit strong immune responses in porcine epidemic diarrhea inactivated vaccine
He et al. Cistanche deserticola polysaccharide-functionalized dendritic fibrous nano-silica as oral delivery system for H9N2 vaccine to promote systemic and mucosal immune response

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20231017

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20250214

Comment text: Request for Examination of Application